• Users Online: 60
  • Print this page
  • Email this page
Year : 2022  |  Volume : 28  |  Issue : 1  |  Page : 83-87

An observational study to evaluate the efficacy of micronised purified flavonoid fraction in improving venous clinical severity score

Department of General Surgery, Government Medical College, Kozhikode, Kerala, India

Correspondence Address:
Dr. G Adhip
Department of General Surgery, Government Medical College, Kozhikode, Kerala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ksj.ksj_9_22

Rights and Permissions

Background: Medical care of chronic venous disease (CVD) entails different strategies that can be used either alone or in combination. Micronised purified flavonoid fractions (MPFFs) are venomodulator drugs used for CVD. Aim: In the present study, the efficacy of MPFF in lowering Venous Clinical Severity Scoring (VCSS) for CVD [Clinical, Etiological, Anatomical and Pathological (CEAP) C3 disease] is assessed and identified a subgroup who will benefit from the therapy. Materials and Methods: This was an observational study based on 35 cases of CVD CEAP Class C3 attending a tertiary hospital. Their initial VCSS was assessed and the same was reassessed after 6 months of MPFF therapy. The data were statistically analysed. Results: The mean age among the study participants was 45.9 ± 9.4 years. Almost half of the study participants, 16 (45.7%), belonged to 41–50 years. More than half of the study participants were female. The median pain score was statistically significantly lower after flavonoid administration compared to baseline (P < 0.001). Similarly, statistically significant lower median oedema and VCSS scores were obtained after flavonoid administration (P < 0.001). However, no significant decrease was observed in the VCSS after flavonoid administration. The median VCSS was statistically significantly lower in females aged 41–50 years after flavonoid administration compared to baseline (P < 0.001). Conclusion: MPFFs are efficient in lowering VCSS in CEAP Class C3 cases of CVD in all age groups. The best efficiency was noted in 41–50 years' age group females. Patients with venous pain and venous oedema had the best response. The least response was noted in clinically demonstrable varices.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal